Literature DB >> 16960254

Unlabeled uses of nebulized medications.

Mary Beth Shirk1, Kevin R Donahue, Jill Shirvani.   

Abstract

PURPOSE: The uses, dosing recommendations, benefits, and disadvantages of unlabeled drugs administered by nebulization are reviewed.
SUMMARY: Nebulization is gaining popularity as a treatment alternative, and many drugs are used unlabeled in a nebulized form, including the opioids, lidocaine, magnesium sulfate, amphotericin B, and colistin. The opioids are frequently used to treat dyspnea in end-stage diseases. Common dosages include 1-2 mg every two hours as needed for hydromorphone and 25-50 microg every two hours for fentanyl citrate. Lidocaine can be used to relieve bronchoconstriction and cough symptoms as well as acting as a local anesthetic. It is typically given in a dose between 20 and 160 mg. Nebulized magnesium sulfate can be used in managing acute asthma and is given in dosages between 125 and 250 mg every 20 minutes, with no more than four consecutive doses. Nebulized amphotericin B can be used to prevent infections in immunocompromised patients. A typical amphotericin B regimen is 25 mg every 24 hours. Nebulized colistin is being studied in the prevention and treatment of gram-negative infections and in patients awaiting lung transplants. Colistin is often given as 75 mg every 12 hours to combat infections.
CONCLUSION: Unlabeled nebulization of opioids, lidocaine, magnesium, amphotericin B, and colistin is an alternative method of treatment for patients with pulmonary problems or infections or for those undergoing bronchoscopy. More research is needed to develop guidelines for their use since nebulization may provide benefits to many patients who otherwise cannot be treated or would be at risk of systemic adverse effects of the drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960254     DOI: 10.2146/ajhp060015

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

1.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

2.  Inhaled antimicrobial therapies for respiratory infections.

Authors:  Shin-Woo Kim; Joseph L Kuti; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

Review 3.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

4.  Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker.

Authors:  Ivan Tochitsky; Sooyeon Jo; Nick Andrews; Masakazu Kotoda; Benjamin Doyle; Jaehoon Shim; Sebastien Talbot; David Roberson; Jinbo Lee; Louise Haste; Stephen M Jordan; Bruce D Levy; Bruce P Bean; Clifford J Woolf
Journal:  Br J Pharmacol       Date:  2021-06-21       Impact factor: 9.473

5.  The efficacy of nebulized furosemide and salbutamol compared with salbutamol alone in reactive airway disease: a double blind randomized, clinical trial.

Authors:  Kambiz Masoumi; Arash Forouzan; Maryam Haddadzadeh Shoushtari; Samaneh Porozan; Maryam Feli; Mehdi Fallah Bagher Sheidaee; Ali Asgari Darian
Journal:  Emerg Med Int       Date:  2014-04-27       Impact factor: 1.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.